Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2337 Target Snapshot

Sodium- and chloride-dependent glycine transporter 1 · SINGLE PROTEIN · Homo sapiens

1,784Compounds
88Assays
1Approved Drugs
2,061.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Sodium- and chloride-dependent glycine transporter 1 shows late clinical disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P48067. Start with schizophrenia, then reuse UniProt P48067 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with schizophrenia, then reuse UniProt P48067 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs
Open source guide
Disease program
schizophrenia

Sodium- and chloride-dependent glycine transporter 1 shows late clinical disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with schizophrenia because it currently carries late clinical support. Linked drugs include BITOPERTIN, ORG-25935, PF-03463275. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sodium- and chloride-dependent glycine transporter 1 as ChEMBL target CHEMBL2337, mapped to UniProt P48067. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sodium- and chloride-dependent glycine transporter 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2337
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P48067
Sodium- and chloride-dependent glycine transporter 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Sodium- and chloride-dependent glycine transporter 1 is the right protein anchor across sources, using UniProt P48067 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why schizophrenia is currently framed as late clinical support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSodium- and chloride-dependent glycine transporter 1
UniProt AccessionP48067
Component TypeProtein
Sequence Length706 aa

Sodium- and chloride-dependent glycine transporter 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Sodium- and chloride-dependent glycine transporter 1, mapped to UniProt P48067. Sequence length is 706 aa.

Mapped IDP48067
Review nameSodium- and chloride-dependent glycine transporter 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Sodium- and chloride-dependent glycine transporter 1 shows late clinical disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
schizophrenia
3 linked drugs · 3 direct · 3 efficacy
Linked drugBITOPERTIN
Linked drugORG-25935
Linked drugPF-03463275
Clinical signal Phase II
alcohol dependence
1 linked drug · 1 direct · 1 efficacy
Linked drugORG-25935
Clinical signal Phase II
Beta-thalassemia
1 linked drug · 1 direct · 1 efficacy
Linked drugBITOPERTIN
Clinical signal Phase II
erythropoietic protoporphyria
1 linked drug · 1 direct · 1 efficacy
Linked drugBITOPERTIN
Clinical signal Phase II
obsessive-compulsive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugBITOPERTIN
Clinical signal Phase II
panic disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugORG-25935
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with schizophrenia because it currently carries late clinical support. Linked drugs include BITOPERTIN, ORG-25935, PF-03463275. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseschizophrenia
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
2
Phase III
3
Phase II
Assay Mix

Activity Type Distribution

IC50976.0
KI695.0
EC50387.0
KD3.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL485356 10.0 IC50 0.1 Preclinical
CHEMBL483938 9.51 IC50 0.31 Preclinical
CHEMBL180966 9.41 IC50 0.39 Preclinical
CHEMBL379668 9.33 IC50 0.47 Preclinical
CHEMBL521463 9.19 IC50 0.65 Preclinical
CHEMBL4593786 9.17 IC50 0.671 Preclinical
CHEMBL4526580 9.14 IC50 0.726 Preclinical
CHEMBL4468117 9.13 IC50 0.733 Preclinical
CHEMBL26512 9.1 Kd 0.8 Preclinical
CHEMBL4161906 9.1 Ki 0.8 Preclinical
Distribution

pChEMBL Value Distribution

66
5.0
96
5.5
135
6.0
175
6.5
215
7.0
183
7.5
116
8.0
81
8.5
25
9.0
1
9.5
pChEMBL
Assay Landscape

Assay Landscape

88
Total Assays
1,040
Tested Compounds
2
Assay Types
Binding — 83 assays, 1,040 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 50 717 7.2
single protein format 24 281 6.6
assay format 9 42 6.2
Functional — 5 assays, 39 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 4 4 8.2
assay format 1 35 6.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine